Concurrent follicular lymphoma and follicular dendritic cell sarcoma: composite neoplasm or transdifferentiation?

Mahsa Hajizadeh, Jinbo Fan, Jeffrey W Craig, Ifeyinwa E Obiorah

Abstract readCase Reports

In one paragraph

Article in Journal of hematopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mahsa HajizadehDepartment of Pathology, University of Virginia Health, Charlottesville, VA, USA.

Jinbo FanDepartment of Pathology, University of Virginia Health, Charlottesville, VA, USA.

Jeffrey W CraigDepartment of Pathology, University of Virginia Health, Charlottesville, VA, USA.

Ifeyinwa E ObiorahDepartment of Pathology, University of Virginia Health, Charlottesville, VA, USA. JNP5QM@uvahealth.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Follicular dendritic cell sarcoma (FDCS) is a rare neoplasm, and its synchronous occurrence with follicular lymphoma (FL) has not been reported. Whether composite tumors arise independently or through clonal evolution remains unclear. A 52-year-old woman presented with night sweats, weight loss, and an obstructing hepatic flexure colonic mass with mesenteric disease. Biopsy showed two tumor populations: an atypical B cell infiltrate positive for CD20, CD10, focal BCL6, and weak/focal MUM1, with kappa predominance and Ki-67 of 20-50%, consistent with follicular large B cell lymphoma/FL grade 3B, and epithelioid-to-spindled cells expressing CD21, CD23, CD35, CXCL13, and D2-40 and lacking B cell and epithelial markers, supporting FDCS. Fluorescence in situ hybridization demonstrated shared BCL6 rearrangements, IGH and MYC copy-number gains in both components, IGH rearrangement testing was negative, and next-generation sequencing identified alterations in JAK1, APC, FGFR4, NOTCH3, and TSC1. This case highlights biologic challenges in distinguishing transdifferentiation from synchronous neoplasms.

Indexed as

Cell TransdifferentiationColonic NeoplasmsDendritic Cell Sarcoma, FollicularLymphoma, FollicularNeoplasms, Multiple PrimaryBiopsyColon, AscendingDiagnosis, DifferentialFemaleHumansMiddle AgedComposite lymphomaFluorescence in situ hybridizationFollicular dendritic cell sarcomaFollicular lymphomaTransdifferentiation

Identifiers

PMID42799816

DOI10.1007/s12308-026-00736-z

PMCPMC13615919

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.